In vivo, the anti-tumor efficacy of RORγ inhibition was evaluated using subcutaneous xenograft and experimental metastasis models.<h4>Results</h4>We identify RORγ as a key driver of NSCLC progression. The gene discussed is RORC; the disease is non-small cell lung carcinoma.